Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Reform A Reality: Costs And Opportunities Ahead

This article was originally published in The Gray Sheet

Executive Summary

Comprehensive patent reform, which finally passed Congress last week after six years of debate, is likely to add new costs and uncertainties for device companies, but also important new opportunities for the most proactive of firms, patent attorneys say.
Advertisement

Related Content

A Post-IPR World Would Hold Patent Risks And Benefits For Medtech Companies
Stryker-Zimmer Case Sets Up Tech Industry, Government Clash On Patent Damages Issue
High Court Won’t Hear Covidien Patent Appeal
J&J Lawyer Considered To Lead U.S. Patent Office
Patent-Reform Risks Remain For Device Firms In Lawmaker Efforts
News In Brief
News In Brief
Patent Reform Makes Another Run Toward Finish Line
Patent Reform Makes Another Run Toward Finish Line

Topics

Advertisement
UsernamePublicRestriction

Register

MT030527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel